Shots:

• With the noble responsibility of ensuring a healthy society on their shoulders, biopharma companies focused on Immunology are diligently working to develop treatments, vaccines, antibodies, and drugs
• The global Immunology market was valued at $97.93B in 2021 and is anticipated to reach $184.21B by 2029 with a CAGR of 8.5 percent. In 2022, AbbVie retained its position with a revenue of $28.92B, followed by Johnson & Johnson and Sanofi with revenue of $16.93B and $9.82B respectively
• PharmaShots brings a concise report on the Top 20 Immunology Companies based on 2022 total Immunology Segment Revenue

Immunology Segment Revenue: $74.05M

Founded Year: 1993

Market Cap: $2.19B

Total Employees: $2.21B

Headquarters: Shenyang, China

Stock Exchange: HKG

A China-based biotech company, 3S Bio develops and commercializes biopharmaceutical products in addition to recombinant or genetically engineered, protein-based products. The company focuses on multiple therapy areas, that include Oncology, Nephrology, Dermatology, and Auto-immune diseases. Yisaipu is the company’s lead product in its immunology segment. 3S Bio’s immunology segment revenue decreased by 40.33% in 2022 vs 2021. The fall in the sales of Yisaipu was attributed to the decrease in medical consultation demand. In Jul’22, 3S Bio entered into a license agreement with COSMO Pharmaceuticals for the development and commercialization of Winlevi in Greater China.

Immunology Segment Revenue: $116M

Founded Year: 1923

Market Cap: $219.15B

Total Employees: ~83,500

Headquarters: Cambridgeshire, United Kingdom

Stock Exchange: LON

AstraZeneca is a multinational pharma and biotech company that discovers and develops innovative medicines. Products developed and commercialized by the company focus on oncology, cardiology, gastrointestinal infections, and inflammation. Under its Immunology segment, the company develops Saphnelo for the treatment of Systemic Lupus Erythematosus (SLE). AstraZeneca’s sales for immunology were boosted from $8M in 2021 to $118M in the year 2022 led by the approval of Saphnelo in the EU. In Feb’22, AstraZeneca received approval for Saphnelo (anifrolumab) in the EU for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE).

Immunology Segment Revenue: $826.96M

Founded Year: 2007

Market Cap: $9.08B

Total Employees: ~6,400

Headquarters: Osaka, Japan

Stock Exchange: TYO

Committed to the production and distribution of therapeutic products, Mitsubishi Tanabe Pharma is a pharma company with a renowned name in the field of Immunology. Diabetes, Kidney Diseases, Autoimmune Diseases & Vaccines are some of the therapy areas that the company focuses on. The company’s Immunology segment comprises Stelera, Simponi & Imusera (Gilenya). The immunology segment revenue of the company is a contribution to the sales of Stelera and Simponi in addition to the royalties earned from Novartis for Imusera (Gilenya). Mitsubishi’s segment revenue rose by 1.81% in 2022 vs 2021. In May’22, Mitsubishi Tanabe Pharma’s Radicava ORS received the US FDA’s approval for the treatment of ALS.

Immunology Segment Revenue: $913M

Founded Year: 1891

Market Cap: $270.01B

Total Employees: ~69,000

Headquarters: New Jersey, United States

Stock Exchange: NYSE

A multi-disciplinary company, Merck & Co. develops and commercializes therapeutic products under its Pharmaceutical and Animal Health division. Oncology, Infectious Diseases, Respiratory, and Immunology are areas under which the company develops varying therapeutic entities. Simponi and Remicade are the two products contributing to the total sales generated by its Immunology segment. Merck’s 2022 revenue dropped by 18.77% as compared to 2021. The decrease in revenue could be ascribed due to the lower sales of both Simponi and Remicade. In Nov’22, Merck & Co. reported the acquisition of Imago BioSciences.

Immunology Segment Revenue: $1.49B

Founded Year: 1923

Market Cap: $27.51B

Total Employees: ~14,500

Headquarters: Tokyo, Japan

Stock Exchange: TYO

A Japan-based multinational pharma company, Astellas, discovers, develops, and commercializes a wide range of pharmaceutical products. The company majorly focuses on therapeutic areas, including Cardiology, Hematology, Immunology, Infectious Diseases, Oncology, and Urology. The sales of Prograf generated the company’s net Immunology revenue. In 2022, Astellas’ immunology segment revenue decreased by 1.96% as compared to 2021. In Jun’22, Astellas entered into a worldwide strategic collaboration and licensing agreement with Sutro Biopharma for the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs).

Immunology Segment Revenue: $2.03B

Founded Year: 1978

Market Cap: $39.70B

Total Employees: ~8,700

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

Biogen is a multinational biopharma company that develops and commercializes innovative medicines across various therapeutic areas. The company provides therapeutic options for Autoimmune, Neurology, and Neurodegenerative Diseases. Its net immunology segment revenue was generated through its product Tysabri. Biogen’s 2022 revenue declined by 1.56% as compared to 2021. The fall in the sales of Tysabri in 2022 was due to the increase in its pricing net of higher discounts and allowances. In Oct’22, Biogen reported the first patient dosing in the P-II/III (AMETHYST) clinical trial evaluating the safety and efficacy of Litifilimab in patients with cutaneous lupus erythematosus (CLE).

Immunology Segment Revenue: $2.09B

Founded Year: 2008

Market Cap: $23.83B

Total Employees: ~2,100

Headquarters: Dublin, Ireland

Stock Exchange: NASDAQ

A global biopharma company, Horizon Therapeutics focuses on the discovery, development, and commercialization of therapeutic products for the treatment of autoimmune & severe inflammatory diseases. The products adding to the company’s net immunology revenue include Tepezza, Rayos, Duexis, Vimovo & Pennsaid with around $1.96B contribution from the sales of Tepezza. Horizon’s immunology segment revenue in 2022 increased by 4.81% as compared to 2021. The slight increase in the net sales of the company could be attributed to the increase in the sales of Tepezza due to volume growth and higher net pricing. In Nov’22, Horizon Therapeutics entered into a research collaboration and option agreement with Xeris Biopharma to develop and commercialize innovative products for various indications, including Tepezza to treat Thyroid Eye Disease.

Immunology Segment Revenue: $2.27B

Founded Year: 1928

Market Cap: $17.41B

Total Employees: ~8,700

Headquarters: Brussels, Belgium

Stock Exchange: EBR

UCB is a biopharma company that develops and commercializes therapeutic entities. The company focuses on developing products targeting Neurology and Immunology. Cimzia and Bimzelx are the two key contributors to the net revenue of UCB’s immunology segment. UCB’s 2022 revenue increased by 8.39% vs 2021. The performance of net immunology sales improved due to the rise in purchases of Cimzia and Bimzelx. In Mar’22, UCB reported the completion of its acquisition of Zogenix.

Immunology Segment Revenue: $2.41B

Founded Year: 2002

Market Cap: $14.46B

Total Employees: ~2,300

Headquarters: Delaware, United States

Stock Exchange: NASDAQ

Driven by a noble aim to discover and develop products for unmet medical conditions, Incyte focuses extensively on Hematology, Oncology, Inflammation, and Autoimmune Disorders. The company’s net revenue owes a significant contribution from the sales of its immunotherapy product Jakafi. Incyte’s immunology revenue in 2022 rose by 12.87% as compared to 2021. The increase in the sales of Jakafi was led by a volume increase of $156.5M and a price increase of $118.2M. In May’22, Incyte received the EC’s approval for Jakafi as a post-steroid treatment for acute and chronic graft-versus-host disease.

Immunology Segment Revenue: $3.16B

Founded Year: 2000

Market Cap: $71.95B

Total Employees: ~69,400

Headquarters: London, United Kingdom

Stock Exchange: LON

A British multinational healthcare company, GSK discovers and develops therapeutic products targeting Infectious Diseases, HIV, Immunology, Respiratory, and Oncology. The company functions under three business segments i.e., General Medicine, Specialty Medicine, and Vaccines. The products developed by the company under its immunology segments include Benlysta, Jesduvroq, and Duvroq. The individual sales of Benlysta rose by 31% at AER and 20% at CER, thereby representing a strong underlying demand in the US and globally. GSK’s total immunology segment revenue escalated by 15.07% in 2022 as compared to 2021. In Aug’22, GSK completed the acquisition of Affinivax.

Immunology Segment Revenue: $3.31B

Founded Year: 1849

Market Cap: $201.20B

Total Employees: ~83,000

Headquarters: New York, United States

Stock Exchange: NYSE

A research-based biopharma company, Pfizer is a well-known name in the healthcare sector for the discovery, development, manufacturing, marketing, sales, and distribution of biopharma products across the world. The key therapy areas upon which the company focuses are Oncology, Immunology, Cardiology, Endocrinology, and Neurology. Xeljanz, Enbrel, and Inflectra/Remsima are the products developed under the company’s immunology segment. In 2022, Pfizer’s immunology segment faced a recession of 22.48% as compared to 2021. This decline in the net revenue of the immunology segment can be attributed to the decrease in the sales of Xeljanz or the increasing biosimilar competition for Enbrel in the market. In Mar’22, Pfizer reported the completion of its acquisition of Arena Pharmaceuticals to enhance Pfizer’s Inflammation and Immunology therapeutic area.

Immunology Segment Revenue: $3.34B

Founded Year: 1876

Market Cap: $495.14B

Total Employees: ~21,000

Headquarters: Indianapolis, United States

Stock Exchange: NYSE

To produce products for patients with unmet needs, Eli Lilly and Company works extensively in discovering, developing, manufacturing, and marketing such therapeutic products. The therapeutic areas targeted by the company are Diabetes, Oncology, Immunology, and Neuroscience. The company’s immunology segment revenue was generated through the sales of products including Taltz and Olumiant among others. Eli Lilly’s 2022 immunology revenue declined by 0.48% as compared to 2021. The immunology segment revenue decreased due to the decline in the sales of Olumiant. In Jun’22, Eli Lilly and Incyte’s Olumiant received the US FDA’s approval to treat adult patients with Severe Alopecia Areata.

Immunology Segment Revenue: $3.46B

Founded Year: 1887

Market Cap: $125.68B

Total Employees: ~34,300

Headquarters: New York, United States

Stock Exchange: NYSE

Indulging in the development and commercialization of a wide range of products, Bristol-Myers Squibb (BMS) is a multinational biopharma company and a renowned name in the pharma industry. The company develops innovative medicines for patients with serious diseases targeting therapy areas, including Oncology, Cardiovascular, and Immunological Diseases. Orencia is the product contributing to the company’s immunology segment revenue. BMS’s immunology segment revenue in 2022 increased by 4.48% vs 2021. The increase in sales was led by the increasing demands of Orencia in 2022 as compared to 2021. In Jun’22, BMS reported a definitive merger agreement to acquire Turning Point Therapeutics for $76.00 per share.

Immunology Segment Revenue: $5.11B

Founded Year: 1781

Market Cap: $48.89B

Total Employees: ~50,000

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Takeda is a Japanese multinational biopharma company that discovers, develops, and commercializes therapeutic entities for Metabolic Disorders, Gastroenterology, Neurology, Inflammation, Immunology, and Oncology. Immunoglobulin & Albumin are the company’s approved immunotherapies contributing to its net segment revenue. Takeda’s 2022 immunology segment revenue spiked by 22.33% as compared to 2021. The immunology segment sales of the company rose due to continued strong demand globally, growing supply (especially in the US and China), and favorable exchange rates. In Dec’22, Takeda reported the acquisition of NDI-034858 from Nimbus Therapeutics for multiple autoimmune diseases.

Immunology Segment Revenue: $6.40B

Founded Year: 1980

Market Cap: $139.35B

Total Employees: ~25,200

Headquarters: California, United States

Stock Exchange: NASDAQ

A biotech company, Amgen indulges in the business to discover and develop treatment options to aid patients with unmet healthcare needs. CVD, Oncology, Bone Health, Neuroscience, Immunology, Nephrology, and Inflammation are the therapy areas for which the company develops products. The net immunology segment revenue of the company was contributed by Enbrel & Otezla. Amgen’s immunology segment revenue dropped by 4.60% in 2022 as compared to 2021. As a result of unfavorable changes to Enbrel's estimated sales deductions, the immunology segment's sales decreased. In Aug’22, Amgen reported the acquisition of ChemoCentryx, including its product Tavneos for the treatment of patients with serious autoimmune diseases.

Immunology Segment Revenue: $7.29B

Founded Year: 1996

Market Cap: $235.05B

Total Employees: ~102,000

Headquarters: Basel, Switzerland

Stock Exchange: SWX

A multinational healthcare company, Novartis discovers, develops, and commercializes breakthrough therapies for the treatment of unmet healthcare needs. The company focuses on Oncology, Hepatology, Immunology, Dermatology, Musculoskeletal Diseases, Neurosciences, and Ophthalmology. The immunology segment of the company includes Cosentyx, Xolair, and Ilaris. Novartis’ 2022 revenue increased by 1.14% vs 2021. In Sep’22, Novartis reported the results from the P-III (SUNSHINE) and (SUNRISE) clinical trials evaluating Cosentyx in patients with moderate to severe hidradenitis suppurativa (HS).

Immunology Segment Revenue: $7.77M

Founded Year: 1896

Market Cap: $249.48B

Total Employees: ~1,03,600

Headquarters: Basel, Switzerland

Stock Exchange: SWX

A Swiss-based multinational biopharma company, Roche dedicatedly discovers and develops therapeutic products under its Pharmaceutical and Diagnostics division. Under its immunology segment, the company delivers products for Rheumatoid Arthritis, Systemic Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, and Giant Cell Arthritis. Actemra/RoActemra, Xolair, Esbriet, Pulmozyme, CellCept, and MabThera/Rituxan are contributors to its immunology segment revenue. Roche’s 2022 immunology segment revenue decreased by 15.41% as compared to 2021. The decrease in the sales of the company’s immunology segment was partly led by the higher sales of Xolair in the US. In Mar’22, Roche entered into a collaboration agreement with BMS to support the advancement of two assays to be used in clinical trials with the development and deployment of two new digital pathology algorithms.

Immunology Segment Revenue: $9.82M

Founded Year: 2004

Market Cap: $133.54B

Total Employees: ~91,573,400

Headquarters: Paris, France

Stock Exchange: NASDAQ

Sanofi is a multinational healthcare company known for the development and commercialization of therapeutic entities and functions under its business segment, including Pharmaceuticals, Vaccines, and Consumer Health. Oncology, Cardiovascular, Neurology, Immunology, and Inflammation are the therapy areas targeted by Sanofi. The company’s immunology segment revenue is the net of sales of the products Dupixent & Kevzara. Sanofi’s 2022 immunology segment revenue was boosted by 55.92% as compared to 2021. The company’s immunology segment revenue marked a significant increase due to the high demand in sales of Dupixent. In Nov’22, Sanofi entered a multi-year, multi-target strategic research collaboration with Insilico Medicine to advance its drug development process by leveraging Insilico’s Pharma.AI platform.

Immunology Segment Revenue: $16.93B

Founded Year: 1886

Market Cap: $450.09B

Total Employees: ~152,700

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Johnson & Johnson (JnJ) is a multination American healthcare company that discovers, develops, and commercializes therapeutic entities to fulfill patients’ needs. The company focuses on Neuroscience, Oncology, Immunology, Cardiovascular, Metabolism, and Pulmonary Hypertension. Under its immunology segment, the company comprises Remicade, Simponi/Simponi Aria, Stelara, and Tremfya. JnJ’s 2022 revenue increased by 1.10% as compared to 2021. The slight increase in the sales of the company’s immunology segment was driven by the strong uptake of Stelara for the treatment of Crohn’s Disease and Ulcerative Colitis strengthened by the strong uptake for Tremfya for the treatment of Psoriasis and Psoriatic Arthritis. In Aug’22, JnJ’s Stelara received the US FDA’s approval to treat pediatric patients with active Psoriatic Arthritis (PsA).

Immunology Segment Revenue: $28.92B

Founded Year: 2013

Market Cap: $263.97B

Total Employees: ~50,000

Headquarters: Illinois, United States

Stock Exchange: NYSE

AbbVie is a reputed name in the pharma industry that discovers and develops innovative medicines to treat complex health conditions. The company focuses on Immunology, Oncology, Neuroscience, Eye Care, Virology, Women’s Health, and Gastroenterology. The company’s immunology segment generates revenue from the sales of Humira, Skyrizi, and Rinvoq. Out of the company’s immunology products, the sales of Skyrizi rose by 78% in 2022 vs 2021 driven by the continued strong volume and market share uptake since its launch as a treatment for Plaque Psoriasis. AbbVie’s immunology segment revenue boosted by 14.60% in 2022 as compared to 2021. In Jun’22, AbbVie’s Skyrizi received the US FDA’s approval to treat adults with moderate to severely active Crohn’s Disease.

Sources:

• Annual reports
• SEC filings
• Press releases
• Company websites

Market Cap Source: Google Finance (August 09, 2023)

Currency Conversion: X-Rates (August 09, 2023)

Note:

• All revenues are reported in $B
• The revenue for Astellas increased in JPY but decreased in USD due to the currency rate drop

Related Post: Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue